Clinical Trials Browser

Phase 3 × Withdrawn × Alemtuzumab × Clear all

NCT00226512 2011-04-08

To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning

Phase 3 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute